Clinical trials: Breast Cancer, Metastatic
Cancer
Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of aminocamptothecin in treating patients with advanced…
- Trial name
- NCT00003548
- Testing
- aminocamptothecin colloidal dispersion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- NYU Langone Health
Breast Cancer
Breast Cancer Molecular Subtypes and Skeletal Metastases Patterns on Bone Scintigraphy
The goal of this observational study is to evaluate the association between different molecular subtypes of breast cancer and their specific patterns of skeletal metastases on Technetium-99m MDP bone scintigraphy.
- Trial name
- NCT07750340
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Inflammatory Breast Cancer
Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer
Multi-center, non randomised, open label, non controlled pilot study. Evaluating the treatment of bevacizumab in association with pre-operative chemotherapy, followed by surgery, adjuvant chemotherapy and radiotherapy in Patients…
- Trial name
- Beva (NCT01880385)
- Testing
- Bevacizumab, Cyclophosphamide, epirubicin hydrochloride
- Where
- Tunisia
- Volunteers
- 30 people
- Sponsor
- Association Tunisienne de lutte Contre le Cancer
Triple Negative Breast Cancer Metastatic
Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel
This study will evaluate the efficacy and safety of ceralasertib followed by durvalumab plus nab-paclitaxel in 37 patients with TNBC, whose tumor relapsed following treatment with curative intent for early disease, which must…
- Trial name
- ATRiBRAVE (NCT05582538)
- Testing
- Ceralasertib, Durvalumab, Nab-paclitaxel
- Where
- 6 sites in Italy
- Volunteers
- 37 people
- Sponsor
- IFOM ETS - The AIRC Institute of Molecular Oncology
Metastatic Breast Cancer
A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer
This study will use proteomic and genomic profiling to analyze tumor tissue to see if treatment selected by this analysis will benefit patients.
- Trial name
- SO2 (NCT01919749)
- Testing
- treated recommended
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Translational Drug Development
Metastatic Breast Cancer, Central Nervous System (CNS) Metastases
Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
The purpose of this study is to see if capecitabine can be taken safely with different doses of lapatinib in patients with HER-2 positive breast cancer involving brain (brain metastases) and/or in spinal fluid (leptomeningeal…
- Trial name
- NCT02650752
- Testing
- Lapatinib in Tandem With Capecitabine
- Where
- 9 sites in United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Breast Cancer
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
The goal of this study is to test the efficacy of using a 12-week, home-based, unsupervised aerobic and resistance training exercise program for changes in cancer-related fatigue in patients with metastatic breast cancer who are…
- Trial name
- ENERGIZE (NCT07203378)
- Testing
- Whole-body resistance training and aerobic exercise
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Utah
Breast Cancer
Metabolomics Explores Biomarkers for Metastatic Breast Cancer
RATIONALE: Studying samples of plasm by metabolomics-based approach from women with metastasis breast cancer may help doctors understand the biomarker of visceral metastasis.
- Trial name
- NCT04302415
- Testing
- There is no other intervention, only clinical treatment.
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Shandong Cancer Hospital and Institute
Locally Recurrent, Metastatic Breast Cancer ( HER2 Negative)
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
The purpose of this study is to assess the efficacy and safety of single-agent eribulin mesylate for first-line treatment of subjects with locally recurrent or metastatic breast cancer.
- Trial name
- NCT01268150
- Testing
- Eribulin mesylate
- Where
- 17 sites in United States
- Volunteers
- 56 people
- Sponsor
- Eisai Inc.
Breast Cancer, Metastasis
Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer
This is an open-label, non-comparative efficacy and safety study of Capecitabine and Mitomycin C as first-line treatment in patients with previously untreated metastatic breast cancer.
- Trial name
- NCT01196455
- Testing
- Capecitabine and Mitomycin C
- Where
- Croatia
- Volunteers
- 39 people
- Sponsor
- Croatian Cooperative Group for Clinical Research in Oncology
Circulating Tumor Cells (CTCs)
Collection of Circulating Tumor Cells From the Peripheral Blood of Metastatic Breast Cancer Patients
To address the challenges of isolating and analyzing rare cells, this study aims to validate the instrumentation, the test protocols, and the analysis of patient's outcome to show the instrument's capability to reproducibly and…
- Trial name
- NCT02904135
- Where
- Taiwan
- Volunteers
- 141 people
- Sponsor
- MiCareo Taiwan Co., Ltd.
Breast Cancer
HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes
This is a retrospective, observational study that will document the treatment patterns and clinical outcomes of patients diagnosed with HR+/HER2- A/MBC who received CDK4/6i combination therapy with aromatase inhibitors (AI) as…
- Trial name
- NCT04396626
- Where
- United States
- Volunteers
- 975 people
- Sponsor
- Pfizer
Breast Cancer Metastatic, Breast Cancer Female
Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.
Targeted therapy in the treatment of breast cancer targets HER2 receptor (Human Epidermal growth factor Receptor). HER2 receptor plays an important role in cell growth and differentiation (5).
- Conditions
- Breast Cancer Metastatic, Breast Cancer Female, Breast Cancer Recurrent
- Trial name
- NCT05301530
- Testing
- Faceptor, Herceptin, Docetaxel
- Where
- 2 sites in Vietnam
- Volunteers
- 50 people
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
Breast Cancer
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
This trial will evaluate the clinical significance of the PRO Onc assay and will assess the efficacy of HER2-targeted therapy in patients with HER2-negative breast cancer who have been identified as having HER2…
- Trial name
- NCT01048099
- Testing
- PRO Onc Assay and Treatment, Trastuzumab, Pertuzumab
- Where
- 7 sites in United States
- Volunteers
- 283 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
Low Dose of Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer
The purpose of this study is to evaluate the role of low dose metronomic cyclophosphamide and capecitabine in pretreated metastatic breast cancer.
- Trial name
- NCT01526512
- Testing
- metroCX
- Where
- 2 sites in China
- Volunteers
- 72 people
- Sponsor
- Fudan University
Breast Cancer
Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer
A Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety of a Single Agent Docetaxel 2-Weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer to a 3-Weeks Regimen
- Trial name
- NCT03147963
- Testing
- Docetaxel
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
The primary objective of this study is to determine if estrogen receptor-targeted therapy with fulvestrant used in combination with Everolimus is an effective and safe therapy for women with hormone receptor positive metastatic…
- Trial name
- BRE-43 (NCT00570921)
- Testing
- Everolimus, Fulvestrant
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Mara Chambers
Breast Cancer
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
This single-arm study was designed to evaluate the efficacy and safety of oral Xeloda plus intravenous Avastin as first-line treatment in women with metastatic breast cancer.
- Trial name
- NCT00121836
- Testing
- Capecitabine, Bevacizumab
- Where
- 57 sites in United States
- Volunteers
- 109 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative
The proposed study is a multicenter, open-label phase I trial, conducted in locally advanced or metastatic breast cancer HER2 negative patients and divided into 2 parts: STEP 1: a dose escalation part (n= up to 30) to evaluate…
- Trial name
- GEP14-LEECAP (NCT02754011)
- Testing
- Combination of ribociclib + capecitabine
- Where
- 2 sites in France
- Volunteers
- 18 people
- Sponsor
- UNICANCER
Estrogen Receptor Positive Breast Cancer, Breast Neoplasm
[18F]FES PET/CT in Endocrine Refractory Breast Cancer
In this study, positron emission tomography (PET/CT) imaging will be used to evaluate estrogen receptor (ER) activity in sites of metastatic disease using the investigational radiotracer [18F]fluoroestradiol (FES).
- Conditions
- Estrogen Receptor Positive Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer
- Trial name
- NCT02409316
- Testing
- [18F]FES
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Pennsylvania
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.